Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $958.40 million for the year ending 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +432.1% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from MADRIGAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $0.00 | Q3 2023: $0.00 | Q1 2024: $0.00 | Q2 2024: $14.64 million | Q3 2024: $62.18 million | Q1 2025: $137.25 million | Q2 2025: $212.80 million | Q3 2025: $287.27 million.
- Historical annual values: Fiscal year 2025: $958.40 million | Fiscal year 2024: $180.13 million | Fiscal year 2023: $0.00 | Fiscal year 2022: $0.00.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: